| P/E (FY) | 39.1 | Sales (TTM) | $3.10B |
| Earnings (TTM) | $668.6M | ROE | 16.38% |
| Net Margin | 16.73% | ROIC | 17.16% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | 44.12% | Sales Growth 3Y | 24.32% |
Neurocrine Biosciences, Inc. discovers, develops, and commercializes pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the U.S. and internationally. Marketed products include INGREZZA, Orilissa, Oriahnn, CRENESSITY, ALKINDI, and Efmody. Its clinical pipeline spans candidates for movement disorders, major depressive disorder, schizophrenia, bipolar mania, Alzheimer's disease, epilepsy, and congenital adrenal hyperplasia.
| Market Cap | $18.38B | Trading Days | 5293 |
| 52W High | 182.91 |
| 52W Low | 122.14 |
| % Off High | −0.04% |
| YTD | 28.91% | 1Y | 36.74% |
| 3Y | 77.94% | 5Y | 94.67% |
| 10Y | 264.57% | Since incept. (ann.) | 6.80% |
Reportable 100%
| Ann. Volatility (1Y) | 32.20% | Ann. Volatility (3Y) | 33.65% |
| Sharpe (1Y) | 1.15 | Sharpe (3Y) | 0.76 |
| Max Drawdown (1Y) | −20.90% | Max Drawdown (3Y) | −42.89% |
| Beta (3Y, vs SPY) | 0.52 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| MRNA | Moderna, Inc. | $22.07B | — |
| EXEL | EXELIXIS, INC. | $14.03B | 20.1 |
| BIIB | BIOGEN INC. | $29.55B | 22.8 |
| TECH | BIO-TECHNE Corp | $11.21B | 155.7 |
| KRYS | Krystal Biotech, Inc. | $10.37B | 51.4 |
| HALO | HALOZYME THERAPEUTICS, INC. | $9.66B | 31.8 |
| KYMR | Kymera Therapeutics, Inc. | $9.05B | — |
| QGEN | QIAGEN N.V. | $8.91B | — |
| RVMD | Revolution Medicines, Inc. | $39.98B | — |
| IMVT | Immunovant, Inc. | $8.23B | — |
| APGE | Apogee Therapeutics, Inc. | $8.15B | — |
| PCVX | Vaxcyte, Inc. |
| $8.01B |
| — |
